Search 237 product updates by drug, renal measure or dialysis term. Each result identifies the formulation, the label used and the limits of its renal guidance.
This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.
Renal measure
Creatinine clearance (CrCl), mL/min
Renal action or finding
The label lists silodosin 4 mg once daily with a meal for moderate impairment (CrCl 30-50 mL/min) and contraindicates use below 30.
Limits and monitoring
The cited mild (50-80) and moderate (30-50) ranges both print 50. At exactly 50 verify the current product label and clinical interpretation before choosing a dose.
Renal impairment categories as defined by the cited product label
Renal action or finding
Bowel preparation in renal impairment warrants caution. Maintain adequate hydration and consider checking electrolytes, creatinine and BUN before and after the preparation.
Limits and monitoring
Review diuretics, renin-angiotensin system inhibitors and NSAIDs as potential contributors to renal risk.
In renal impairment select the interval by CrCl, monitor heart rate and QTc, and allow at least five doses at the appropriate interval before increasing the dose.
Limits and monitoring
Use the full initiation or reinitiation protocol. Hemodialysis removes some drug but the label supplies no dialysis regimen.
Measured sotatercept exposure showed no clinically meaningful difference in mild or moderate impairment or in the end-stage kidney disease group receiving dialysis.
Limits and monitoring
Evidence for severe nondialysis impairment is predictive. Check hemoglobin and platelet monitoring before doses.
Renal impairment categories as defined by the cited product label
Renal action or finding
In recipients of a liver, heart or lung transplant with pre-existing renal impairment, consider the low end of the tacrolimus therapeutic dose range because of nephrotoxicity.
Limits and monitoring
Check trough concentrations, kidney function, route and transplant indication.
